Following in the footsteps of Biogen and Roche, Pfizer has acquired a 15% equity interest in gene therapy specialist, Vivet Therapeutics, with an option to acquire the company following the release of Phase I/II clinical trial data for VTX-801. The two companies will also collaborate on the development of VTX-801, which is Vivet’s lead programme and being developed for the treatment of Wilson disease. Preclinical studies for the asset showed sustained long-term efficacy and safety.